The US FDA Grants Breakthrough Therapy Designation to Innate Pharma’s Lacutamab for R/R Sézary Syndrome
Shots:
- The US FDA has granted BTD to lacutamab for the treatment of adults with r/r sézary syndrome after receiving ≥2L of therapy incl. mogamulizumab
- Designation was based on P-I as well as P-II (TELLOMAK) trial data, showing efficacy & favorable safety in pts who were heavily pre-treated with mogamulizumab
- Additionally, Lacutamab (anti-KIR3DL2 mAb) is expected to enter P-III trial for CTCL, with Innate actively seeking a partner
Ref: Businesswire | Image: Innate Pharma
Related News:- Innate Pharma Reports Results from the P-II Study (TELLOMAK) of Lacutamab for Sézary Syndrome
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
